This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
endometrial-cancer
Endometrial Cancer
Most common gynecologic malignancy in the US (~67,000/year); POLE-ultramutated and MSI-H subtypes respond to pembrolizumab; endometrioid type driven by PTEN/PIK3CA/KRAS; serous by TP53/ERBB2. Carboplatin+paclitaxel is standard; dostarlimab approved for dMMR endometrial cancer.
Entry Metadata
| Field | Value |
|---|---|
| ID | endometrial-cancer |
| Name | Endometrial Cancer |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Konstantinopoulos PA, Lheureux S, Moore KN. PARP inhibitors for ovarian and endometrial cancers: state of the art and clinical perspectives. J Clin Oncol. 2020;38(25):2896-2909. · PubMed 32706635
- Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159-2170. · PubMed 37166384